Glatiramer
| Evidence Level: L5 | Predicted Indications: 1 |
Table of Contents
Glatiramer: From Multiple Sclerosis to Hemoglobinopathy
One-Sentence Summary
Glatiramer is an injectable immunomodulator used in multiple sclerosis. The TxGNN model predicts it may be effective for hemoglobinopathy, but there are currently 0 clinical trials and only 1 publication (a case report that does not test this idea), so this is a model prediction without real supporting evidence.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Multiple sclerosis (the US license records provided contain no indication text; this comes from the prediction rationale) |
| Predicted New Indication | Hemoglobinopathy |
| TxGNN Prediction Score | 99.03% |
| Evidence Level | L5 |
| US Market Status | ✓ Marketed |
| Number of NDAs | 16 (the five listed below are ANDAs) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the source record. Glatiramer is generally understood to mimic myelin basic protein and shift T-cell responses toward Th2/regulatory phenotypes. That explains its use in multiple sclerosis, an immune-mediated disease.
Hemoglobinopathies such as sickle cell disease and thalassemia are inherited disorders of globin production or structure. Glatiramer has no plausible disease-modifying target in them, so no direct mechanistic link is supported. The only speculative connection is to immune-mediated complications, such as autoimmune hemolysis or alloimmunization.
The high TxGNN score (0.990) is a computational output only. It should not be read as clinical evidence.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 28372806 | 2017 | Case report | Revue neurologique | A 35-year-old woman with multiple sclerosis and a history of beta thalassemia, bulimia and asthma developed multiple immune disorders after stopping natalizumab. She had previously received first-line subcutaneous immunomodulatory treatments. The report does not evaluate glatiramer as a treatment for hemoglobinopathy. |
US Market Information
The license records provided contain no approved-indication text.
| Authorization Number | Product Name | Dosage Form | Manufacturer |
|---|---|---|---|
| ANDA208468 | Glatiramer Acetate | Injection, solution | Zydus Pharmaceuticals USA Inc. |
| ANDA208468 | Glatiramer Acetate | Injection, solution | Italfarmaco SpA |
| ANDA090218 | Glatopa | Injection, solution | Sandoz Inc |
| ANDA091646 | Glatiramer Acetate | Injection, solution | Mylan Pharmaceuticals Inc. |
| ANDA090218 | Glatopa | Injection, solution | Bryant Ranch Prepack |
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests on a model score alone. There are no registered trials, the only publication is an unrelated case report, and there is no plausible mechanism linking glatiramer to globin disorders.
To proceed, the following is needed:
- The package insert warnings and contraindications (a blocking gap for safety screening)
- Confirmed mechanism of action data from DrugBank
- A specific, testable hypothesis, such as an immune-mediated complication of hemoglobinopathy
- A targeted literature search for preclinical or clinical data in sickle cell disease or thalassemia
- A check of route compatibility (glatiramer is injectable only) against the intended use
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.